Teva Employs Brand-Like Patent Litigation To Retain Generic Zoloft Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm claims in multiple lawsuits that other generic manufacturers are violating patents related to the manufacturing process for sertraline.
You may also be interested in...
Teva Launches First Generic Zoloft
Pfizer counters with “authorized” generic through its Greenstone division.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.